Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies.
A major cause of stroke, as well as other arterial and venous thromboembolic disease has been identified-the presence of antiphospholipid antibodies (aPL). Now it is possible to identify individuals positive for aPL and still free of thrombosis. The tests to measure aPL have been standardized (aCL by ELISA and LA by coagulometric assays) and they are routinely performed in patients with SLE and other connective tissue diseases and women with recurrent pregnancy loss. However, very little is known about the risk of thrombosis in individuals positive for aPL but still free of thrombosis. Should these individuals receive any treatment? If so, which one?
Khamashta
M A
MA
Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK. 106404.2325@compuserve.com
D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000096:biosynthesis* / Q000097:blood; D016736:Antiphospholipid Syndrome / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013927:Thrombosis / Q000276:immunology* / Q000517:prevention & control*
D017152:Antibodies, Antiphospholipid